Stay updated on Ponatinib for Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Ponatinib for Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Ponatinib for Medullary Thyroid Cancer Clinical Trial page
- Check5 days agoChange DetectedFooter updated to show Revision: v3.3.3 and remove references to HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedRevision: v3.3.2 was added and revision v3.2.0 was removed.SummaryDifference0.1%

- Check40 days agoChange DetectedThe funding-status notice about lapse in government funding has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check55 days agoChange DetectedThe study status is Withdrawn/Closed by sponsor with enrollment at 0, indicating no active recruitment.SummaryDifference0.5%

- Check83 days agoChange Detected- Updated page to v3.2.0 and removed the Medullary thyroid carcinoma resource. - Added a government funding/operating-status notice directing users to NIH and OPM sites for current operations.SummaryDifference5%

- Check91 days agoChange DetectedCore content terminology updated from “Medullary thyroid gland carcinoma” to “Medullary thyroid carcinoma” and the release version updated to v3.1.0.SummaryDifference0.1%

Stay in the know with updates to Ponatinib for Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ponatinib for Medullary Thyroid Cancer Clinical Trial page.